"Making Sense of Neurofilament Light in MS"
Stephen Krieger, MD, associate professor of neurology at the Icahn School of medicine at Mount Sinai discusses multiple sclerosis and neurofilament light chain protein. “That's something the topographical model gets at, which is that progression may insidiously reveal old damage already done. It's something that I know Gavin Giovannoni has talked about as therapeutic lag, particularly in progressive populations. That was one of the concerns about the ASCEND trial.” He added, “It would be almost an early indicator that a drug is having the desired effect. We saw that in another presentation at the AAN. Peter Calabresi presented neurofilament data from a whole array of relapsing-remitting MS studies, demonstrating that high levels of neurofilament predicted lesion burden over time, atrophy, and whether a patient was a responder to therapy.”
— Stephen Krieger, MD, Associate Professor, Neurology, Director, Neurology, Residency Training Program, Icahn School of Medicine at Mount Sinai